Monday, January 11, 2021 Daily Archives

Moss-based expression firm receives €60m in funding

by

German biotech Eleva has received funding to advance its candidate CPV-101, produced using a moss-based expression system. Venture capitalist firm Zukunftshonds Heilbronn has invested up to €60 million ($73 million) in funding to progress drug candidate CPV-101 through the clinic. A spokesperson for Eleva told us “we are developing CPV-101 for kidney-associated complement diseases such as aHUS, IgA Nephropathy, PNH, C3G.†The firm has developed a manufacturing process that produces biopharmaceuticals using moss called BryoTechnology. Eleva told BioProcess Insider “fermentation…

January 11, 2021

Sanofi shells out $1.1bn for immunology MAb maker Kymab

by

Sanofi will gain global rights to KY1005 and a monoclonal antibody discovery and development platform through the addition of Kymab. French pharma giant Sanofi is paying $1.1 billion upfront for Cambridge, UK-based biotech Kymab with a further $350 million depending on potential milestones. The deal brings the fully humanized monoclonal antibody KY1005 to Sanofi’s pipeline, along with four other early clinical and preclinical candidates. According to the firm, the candidate targets immune system regulator OX40-Ligand, “blocking inappropriate activation and proliferation…

January 11, 2021

COVID vaccine success accelerating the mRNA space, MilliporeSigma

by

MilliporeSigma has bolstered its messenger RNA (mRNA) manufacturing offering with the addition of German CDMO AmpTec and its polymerase chain reaction (PCR)-based technology. The deal, financials of which have not been divulged, went through last week and plays into MilliporeSIgma’s strategy to expand its mRNA manufacturing services for both therapeutic modalities and diagnostics. The “technology acquisition,†as MilliporeSigma spokeswoman Rachel Bloom-Baglin describes the deal, comes fresh on the arrival of the first two mRNA vaccines. The US FDA approved both…

January 11, 2021